Boston, MA – July 20, 2010: Boston becomes the center of business development worldwide for biotechnology and pharmaceutical executives during three days in September at BioPharm America™. To be held September 15–17, 2010 at the Marriott Boston Copley Place, BioPharm America is expected to draw the active participation of the large Massachusetts-based life science community, as well as a strong contingent of out of state and international firms.

Daphne Zohar, Founder, Managing Partner, Puretech Ventures, who is moderating the day two plenary session, commented, “BioPharm America will bring together the heads of state of biotech partnering. The issues explored and insights offered coupled with high powered networking make this a dominant partnering event.”

This year’s program is hallmarked by plenary sessions featuring some of the leading biotech dealmakers and scientific thought leaders who will examine the key issues, new business approaches and policy trends impacting strategic decision making.

The New Healthcare Ecosystem: What is Biotech’s Role?
This session will explore how the healthcare system is moving away from the blockbuster model and the traditional discovery and development approach towards a model of more individual and personalized treatments and increased collaboration with the biotech sector. The speakers Mara Aspinall, On-Q-Ity; Deborah Dunsire, Millennium Pharmaceuticals; and Robert Langer, MIT will discuss the new order between the different players in the healthcare system: biotech, pharma, diagnostics, payors, etc. and the impact this is having on drug development and healthcare delivery.

Open Innovation: All for One and One for All?
Arguably a more collaborative approach to academic and industry data would make research faster, cheaper and more efficient. But of course scientists and companies have a legitimate interest in protecting their inventions from infringement. In a world where information is increasingly moving from the private into the public domain, Glen Giovannetti, Ernst & Young LLP, will lead a high level panel in an exploration of a more open approach to medical research.

From the Trenches: Partnering War Stories
What are the hidden factors that can either cement a deal or kill it? Within each organization, there are internal dynamics that can shift the balance in a critical way. Daphne Zohar, Puretech Ventures will get a panel of senior leaders and industry veterans that includes Garry Neil, Johnson & Johnson; Mary Tanner, Peter J. Solomon Company; and Patrick Vallance, GlaxoSmithKline to share case studies of high-profile transactions that were consummated and those that never made it past the altar, with a focus on the key factors that made the difference.

“The partnering outcome is often influenced by politics, personalities, and competing internal programs. The Partnering War Stories panel will explore the internal dynamics that can make or break a deal,” added Zohar.

Partnering at BioPharm America is powered by partneringONE^®, the industry’s most advanced partnering system. Many participants will average up to 20 meetings during the event, not including impromptu conversations at stand-up bistro tables nor the hallway encounters inspired by the contact-intensive ambiance of this landmark meeting.

Social events that aim to break the ice and start conversations include the Welcome Reception set for Tuesday, September 14, and the evening receptions and dinners at the Harvard Club of Boston and in the Exhibit Hall, on September 15 and 16 respectively.

For more detailed information about the program please visit http://www.ebdgroup.com/bpa/program/index.php

 About EBD Group
EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group’s conferences are run with the support of leading corporations and international trade associations, and include:

• BIO-Europe and BIO-Europe Spring^®, Europe’s largest life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
• BioPharm America™, the fastest growing partnering event in North America
• EuroMedtech™, EBD Group’s partnering event for the innovative medical technology industry
• BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
• ChinaBio^® Partnering Forum, the first dedicated biotech/pharma partnering conference in China, co-produced with ChinaBio^® LLC
• Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors

EBD Group’s sophisticated web-based partnering service, partneringONE^®, is used as the partnering engine at numerous third-party events around the world.
Outside of the conference format, EBD Group’s consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.
EBD Group has offices in the USA and Europe.

For more information visit www.ebdgroup.com

Contact:
Constantine Theodoropulos
EBD Group
+1 617 292 7319
ctheodoropulos@ebdgroup.com

 

Back to news